[Featured Stock] PhiloSys Surges on News of COVID-19 Diagnostic Kit Supply
[Asia Economy Reporter Yoo Hyun-seok] Philosis Healthcare is showing strong performance. The news that it will supply diagnostic kits for the novel coronavirus infection (COVID-19) had an impact.
As of 11:08 AM on the 16th, Philosis Healthcare was trading at 1,150 KRW, up 13.30% (135 KRW) compared to the previous trading day.
Hot Picks Today
Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Multi-Million Won Bonuses, Life Is Sweet"—Even Employee Reactions... SK hynix Overtakes Samsung to Claim No. 1 Spot
- "It Costs 100,000 Won for Two Hours"...No Place for Kids to Play if Parents Can't Afford It
- Japanese Teacher Dismissed for Obscene Acts Involving Third-Grade Girl's Water Bottle
On this day, Philosis Healthcare announced that it will supply the 'Gmate COVID-19' diagnostic kit to Italy, Switzerland, Egypt, and Malaysia. This contract was signed respectively with Biogenic S.A (Switzerland·Italy case), A&B Health Supplies SDN. BHD (Malaysia case), and MED CARE EGYPT (Egypt case). The contract size is a total of 11.5 billion KRW over 3 years based on the minimum order amount.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
